Taken together, in this work we have demonstrated that tamoxifen cytotoxicity can be enhanced by blockade of the HH pathway, reflecting a cross-talk between ERα and GLI1 signaling, both in tamoxifen resistant and sensitive breast cancer cells. The gene discussed is GLI1; the disease is breast cancer.